Discontinuation of secondary anti-leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy.
Berenguer
J
J
Servicio de Microbiología y Enfermedades Infecciosas, Hospital Gregorio Marañón, Madrid, Spain.
Cosín
J
J
Miralles
P
P
López
J C
JC
Padilla
B
B
D017088:AIDS-Related Opportunistic Infections / Q000517:prevention & control*; D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use; D000818:Animals; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000706:statistics & numerical data*; D018890:Chemoprevention; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D018314:Leishmania infantum; D007898:Leishmaniasis, Visceral / Q000469:parasitology / Q000517:prevention & control*; D008081:Liposomes / Q000627:therapeutic use; D008297:Male; D008536:Meglumine / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D008875:Middle Aged; D009942:Organometallic Compounds / Q000627:therapeutic use; D012008:Recurrence; D016896:Treatment Outcome
D000981:Antiprotozoal Agents; D008081:Liposomes; D009942:Organometallic Compounds; C068538:liposomal amphotericin B; D008536:Meglumine; D000077485:Meglumine Antimoniate; D000666:Amphotericin B